Table 2 Comparison of mSEPT9 positive rate in clinical features of CRC patients
| Â | Positive | Negative | P value |
|---|---|---|---|
N = 137 | N = 42 | ||
Gender | 1.000 | ||
 Male | 86 (62.8%) | 26 (61.9%) |  |
 Female | 51 (37.2%) | 16 (38.1%) |  |
Age (years) | 60.1 ± 9.97 | 57.4 ± 8.28 | 0.081 |
Tumor size (cm) | 3.26 ± 2.06 | 2.61 ± 1.68 | 0.049 |
T stage | 0.067 | ||
 NR | 2 (1.46%) | 3 (7.14%) |  |
 T1 | 5 (3.65%) | 2 (4.76%) |  |
 T2 | 13 (9.49%) | 9 (21.4%) |  |
 T3 | 92 (67.2%) | 23 (54.8%) |  |
 T4 | 19 (13.9%) | 5 (11.9%) |  |
 TX | 6 (4.38%) | 0 (0.00%) |  |
N stage | 0.066 | ||
 NR | 3 (2.19%) | 3 (7.14%) |  |
 N0 | 45 (32.8%) | 21 (50.0%) |  |
 N1 | 38 (27.7%) | 10 (23.8%) |  |
 N2 | 47 (34.3%) | 8 (19.0%) |  |
 NX | 4 (2.92%) | 0 (0.00%) |  |
M stage | 0.087 | ||
 NR | 2 (1.46%) | 3 (7.14%) |  |
 M0 | 102 (74.5%) | 34 (81.0%) |  |
 M1 | 28 (20.4%) | 5 (11.9%) |  |
 Mx | 5 (3.65%) | 0 (0.00%) |  |
Tumor stage | 0.352 | ||
 NR | 4 (2.92%) | 3 (7.14%) |  |
 I | 16 (11.7%) | 8 (19.0%) |  |
 II | 33 (24.1%) | 11 (26.2%) |  |
 III | 57 (41.6%) | 15 (35.7%) |  |
 IV | 27 (19.7%) | 5 (11.9%) |  |
Hemoglobin (g/L) | 118 ± 22.1 | 122 ± 21.6 | 0.239 |
Platelet (× 109) | 305 ± 103 | 270 ± 66.1 | 0.011 |
Neutrophil (× 109) | 6.11 ± 18.0 | 4.28 ± 2.08 | 0.247 |
lymphocyte (× 109) | 1.89 ± 0.69 | 1.86 ± 0.79 | 0.865 |
Albumin (g/L) | 37.4 ± 4.20 | 37.9 ± 7.16 | 0.656 |
CEA (ng/mL) | 80.0 ± 351 | 73.1 ± 395 | 0.920 |
AFP (ng/mL) | 2.69 ± 1.33 | 3.92 ± 4.34 | 0.085 |
CA125 (U/mL) | 21.4 ± 62.3 | 27.6 ± 64.1 | 0.590 |
CA153 (U/mL) | 9.98 ± 4.90 | 11.1 ± 12.4 | 0.588 |
CA199 (U/mL) | 296 ± 1444 | 42.4 ± 127 | 0.045 |
FIT | 0.209 | ||
 Positive | 123 (89.8%) | 34 (81.0%) |  |
 Negative | 14 (10.2%) | 8 (19.0%) |  |